Business
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: ...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc. Mr. Abraham has more than 25 years of financing, business development, and governance and risk management experience in a broad range of roles encompassing private equity investment transactions, including sales and distribution of alternative investments, in Toronto, New York, Abu Dhabi, Singapore, Kuala Lumpur, and Glasgow, Scotland. Most recently, Mr. Abraham was the Chief Executive Officer of the Financial Services Professional Board (FSPB), where he was responsible for all business development with local and international bodies, including the oversight of all programs and standards setting activities of FSPB to achieve its mission and objectives. Mr. Abraham is a member of the Institute of Corporate Directors Canada, a Committee member of TC309, Standards Council of Canada, and the Institute of Chartered Accountants of Scotland. He holds a bachelor's degree in Accountancy from London Metropolitan University, U.K.\"ACP-01's safety and efficacy profile is very impressive, and it is equally promising to combine it NCP to treat conditions of the central and peripheral nervous system,\" stated Thomas Abraham. \"I very much look forward to financing and leading the team that will study, develop and commercialize NCP-01 and ACP-01 in the neuronal field,\" Mr. Abraham said. \"Mr. Abraham's finance and business relationships spans decades in Toronto, New York, the UAE, Singapore, and Malaysia. He is perfectly suited to lead, finance and build PreCerv into a great company focused on treating conditions of the central and peripheral nervous system for Hemostemix shareholders' benefit,\" stated Thomas Smeenk, CEO. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its saf...